Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease

Archives of Medical Science

Volumn 9, Issue 6, 2013, Pages 1019-1027

  Franczyk Skóra, Beata ^a   Gluba, Anna ^a   Banach, Maciej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bleeding; Chronic kidney disease; Management; Myocardial infarction; Treatment

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; FOSINOPRIL; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; PRAVASTATIN; RAMIPRIL; SARTAN DERIVATIVE; TICAGRELOR; TIROFIBAN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS PATIENT; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; URINARY EXCRETION;

EID: 84892386079     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.39792     Document Type: Article

References (74)

1. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J 2002; 23: 1190-201.
2. Goldenberg I, Subirana I, Boyko V, et al. Relation between renal function and outcomes in patients with non-ST segment elevation acute coronary syndrome: Real-world data from the European Public Health Outcome Research and Indicators Collection Project. Arch Intern Med 2010; 170: 888-95.
3. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syn-drome: Data from the SWEDEHEART register. J Inter Med 2010; 268: 40-9.
4. Franczyk-Skóra B, Gluba A, Banach M, Kozowski D, Mayszko J, Rysz J. Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol 2012; 13: 162.
5. Couser WG, Riella MC. World Kidney Day 2011-Protect your kidneys, save your heart. Arch Med Sci 2011; 7: 1-4.
6. van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Neph 2008; 19: 158-63
7. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Iaina-Levin N, Kobus G, Dobrzycki S. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 2011; 7: 658-64.
8. Nair DR, Mehta S, Mikhailidis DP. Assessing renal function-searching for the perfect marker continues! Arch Med Sci 2011; 7: 565-7.
9. Coats WC, Baig SZ, Alpert MA, Aggarwal K. Management of coronary artery disease in patients with chronic kidney disease. Adv Perit Dial 2009; 25: 125-8.
10. Collet JP, Montalescot G, Agnelli G, et al. Non-ST segment elevation acute coronary syndrome in patients with renal dysfunction: Benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005; 26: 2285-93.
11. Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 2249-55.
12. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-67.
13. Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor: A new platelet aggregation inhibitor in patients with acute coronary syndromes. An im prove-ment of other inhibitors Med Sci Monit 2009; 15: MS24-30.
14. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008; 155: 687-93.
15. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-5.
16. Franczyk-Skóra B, Gluba A, Banach M, Rozentryt P, Po-loski L, Rysz J. Acute coronary syndromes in patients with chronic kidney disease. Curr Vasc Pharmacol 2013; 11: 758-67.
17. Hamm CW, Bassand JP, Agewall S, et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the ma-nagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without per-sistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
18. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: Why, who and when Expert Opin Pharmacother 2010; 11: 2665-74.
19. Barylski M, Mayszko J, Rysz J, Myliwiec M, Banach M. Lipids, blood pressure, kidney-what was new in 2011 Arch Med Sci 2011; 7: 1055-66.
20. Swanepoel CR. Chronic kidney disease is a risk factor for cardiovascular disease. SA Heart J 2007; 4: 38-43.
21. Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events: A retrospective study in an out-patient cardiology practice. Arch Med Sci 2012; 8: 57-62.
22. Lai HM, Aronow WS, Mercando AD, et al. Risk factor reduction in progression of angiographic coronary artery disease. Arch Med Sci 2012; 8: 444-8.
23. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 2002; 137: 563-70.
24. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45: 473-84.
25. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
26. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201-8.
27. Sciahbasi A, Arcieri R, Quarto M, et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol 2010; 13: 18-22.
28. Markuszewski L, Rosiak M, Golanski J, Rysz J, Spychal-ska M, Watala C. Reduced blood platelet sensitivity to aspirin in coronary artery disease: Are dyslipidaemia and inflammatory states possible factors predisposing to suboptimal platelet response to aspirin Basic Clin Pharmacol Toxicol 2006; 98: 503-9.
29. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003; 91: 17-21.
30. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41: 718-24.
31. Berger PB, Best PJM, Topol EJ, et al. The relation of renal function to ischemic and bleeding outcomes with 2 dif-ferent glycoprotein IIb/IIIa inhibitors: The do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005; 149: 869-75.
32. Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: Observations from the PROTECTTIMI-30 trial. J Am Coll Cardiol 2006; 47: 2374-9.
33. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294: 3108-16.
34. Basra SS, Tsai P, Lakkis NM. Antiplatelet and anti-thrombotic therapy in ACS patients with CKD: Antiplatelet and antithrombotic drugs. J Am Coll Cardiol 2011; 58: 2263-9.
35. Torp-Pedersen C, Kober L. Effects of ACE inhibitor tran-dolapril on life expectancy of patients with reduced LVEF after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.
36. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systolic dys-function or heart failure: A combined analysis of three trial. Lancet 2006; 368: 581-8.
37. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
38. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-9.
39. Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004; 6: 673-6.
40. Zannad F, Kessler M, Grunfeld JP, Thuilliez C. FOSIDIAL: A randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol 2002; 16: 353-60.
41. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
42. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-62.
43. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226-32.
44. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. beta-Blocker use in long-term dialysis patients: Asso-ciation with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-71.
45. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeld-sen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009; 25: 1995-2005.
46. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Throm-bolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
47. Edwards NC, Steeds RP, Ferro CJ, Townend JN. The treat-ment of coronary artery disease in patients with chronic kidney disease. Q J Med 2006; 99: 723-36.
48. Athyros VG, Hatzitolios AI, Karagiannis A, et al.; IMPERATIVE Collaborative Group. IMproving the im-PlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multi-factorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
49. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pra-vastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98-104.
50. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-63.
51. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.
52. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
53. Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhaili-dis DP, Banach M. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009; 13: 541-50.
54. Lemos PA, Serruys PW, de Feyter P, et al. Long-term fluvastatin reduces the hazardous effect of renal im-pairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 2005; 95: 445-51.
55. Nikolic D, Nikfar S, Salari P, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of statins on lipid profile in chronic kidney disease patients: A metaanalysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 435-51
56. Nikolic D, Banach M, Nikfar S, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. A metaanalysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important Int J Cardiol 2013; 168: 5437-47.
57. Barylski M, Nikfar S, Mikhailidis DP, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 ran-domized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35-44.
58. Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins in patients with chronic kidney disease-an attempt at recommendations. Curr Med Res Opin 2013; 29: 1419-22.
59. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259-305.
60. Wijns W, Kolh P, Danchin N, et al. Guidelines on myo-cardial revascularization The Task Force on Myo cardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percu taneous Cardio-vascular Interventions (EAPCI). Eur Heart J 2010; 31: 2501-55.
61. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-9.
62. Sica D. The implications of renal impairment among pa-tients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002; 14 (Suppl. B): 30B-7B.
63. Machnicki G, Lentine KL, Salvalaggio PR, Burroughs TE, Brennan DC, Schnitzler MA. Kidney transplant Medicare payments and length of stay: Associations with comorbidities and organ quality. Arch Med Sci 2011; 7: 278-86.
64. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci 2010; 6: 539-44.
65. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block. JACC Cardiovasc Interv 2009; 2: 26-33.
66. Dewey TM, Herbert MA, Prince SL, et al. Does coronary artery bypass graft surgery improve survival among patients with end-stage renal disease Ann Thorac Surg 2006; 81: 591-8.
67. Koc-Zorawska E, Malyszko J, Zbroch E, Malyszko J, My-sliwiec M. Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Arch Med Sci 2012; 8: 1048-52.
68. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol 2013; 45: 1605-12.
69. Babiska M, Holecki M, Prochaczek F, et al. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome Arch Med Sci 2012; 8: 449-54.
70. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins Med Sci Monit 2009; 15: MS1-5.
71. Marenzi G, Cabiati A, Assanelli E. Chronic kidney disease in acute coronary syndromes. World J Nephrol 2012; 1: 134-45.
72. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010; 11: 2575-8.
73. Malyszko J, Banach M. Prediabetes, prehypertension-do we need pre-CKD Curr Vasc Pharmacol 2014; doi: 10.2174/15701611113119990123
74. Fox CS, Muntner P, Chen AY, et al.; Acute Coronary Treat-ment and Intervention Outcomes Network registry. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-STsegment elevation myocardial infarction in patients with chronic kidney disease: A report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121: 357-65.